Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15571988 | 0.94 | LPL (0.38) | LPLLIPGTLR9TLR8TLR7 | |
| SCHEMBL24504339 | 0.88 | LPL (0.42) | LPLLIPGHIF1AF11F2 | |
| SCHEMBL22290411 | 0.85 | DRD2 (0.44) | LPLLIPGTLR9TLR8TLR7 | |
| SCHEMBL14167751 | 0.84 | LPL (0.45) | LPLLIPGHIF1ADRD2F11 | |
| SCHEMBL22804541 | 0.83 | DRD2 (0.43) | LPLLIPGHIF1ADRD2 | |
| SCHEMBL23291582 | 0.82 | LPL (0.42) | LPLLIPGTLR9TLR8TLR7 | |
| SCHEMBL31223090 | 0.82 | DRD2 (0.58) | LPLLIPGDRD2 | |
| SCHEMBL22804954 | 0.81 | SLC18A3 (0.41) | LPLLIPGHIF1ADRD2F11 | |
| SCHEMBL15774976 | 0.81 | SLC18A3 (0.55) | LPLLIPGHIF1ADRD2F11 | |
| SCHEMBL15168175 | 0.79 | TLR9 (0.38) | TLR9TLR8TLR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024193691-A1 | CONJUGATE OF ANTI-ROR1 ANTIBODY AND PBD COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恒瑞医药股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| EP-2632551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-07-06 | — | — | EP | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A1, GUCY1A2 | LPL 773/4885LIPG 80/4885TLR9 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.